Respiratory track expansion - Healthy Yuan and Quanxin Biologics sign exclusive license agreement for QX008N monoclonal antibody
Published Time:
2024-01-26
On January 24, 2024, Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Joincare"), an innovative and research-oriented comprehensive pharmaceutical group, and Jiangsu Quansin Biopharmaceutical Co., Ltd. (hereinafter referred to as "Quansin Bio"), focusing on biotherapies for autoimmune and allergic diseases, jointly announced a strategic cooperation and the signing of an exclusive license agreement for QX008N monoclonal antibody in China (including Hong Kong and Macau).
According to the agreement, Joincare will obtain the exclusive rights to research, develop, manufacture, and commercialize QX008N monoclonal antibody in the cooperation region (mainland China + Hong Kong + Macau) for all developable dosage forms and indications in therapeutic areas such as the respiratory system. Quansin Bio will retain the rights to research, develop, and commercialize QX008N monoclonal antibody outside the cooperation region.
QX008N injection is a recombinant humanized anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody preparation, a Class 1 innovative drug for therapeutic biological products. Currently, this product has obtained two clinical trial approvals in China, for asthma and moderate-to-severe chronic obstructive pulmonary disease (COPD), and one clinical trial approval from the US FDA for severe asthma. Currently, the Ib phase clinical trial of QX008N injection for asthma is underway in China.
Mr. Zhu Baoguo, Chairman of Joincare Group, said: "Joincare continues to increase investment in innovative drug research and development. The cooperation with Quansin Bio will further deepen Joincare's layout in the respiratory system new drug R&D pipeline. We are optimistic about the future market potential of QX008N monoclonal antibody and will accelerate the clinical development of this product to achieve commercialization as soon as possible."
Mr. Qiu Jiyuan, Chairman and CEO of Quansin Bio, said: "We are very pleased to cooperate with Joincare, a leading pharmaceutical company in respiratory treatment. QX008N monoclonal antibody has shown good efficacy and safety in previous trials. We believe that with Joincare's support, the development of QX008N monoclonal antibody will be more efficient, and it can bring new hope to patients with asthma and chronic obstructive pulmonary disease as soon as possible."
With the continuous increase in the incidence of asthma in recent years, the patient population has become increasingly large, making it one of the most prevalent diseases globally, affecting approximately 339 million people worldwide. In China, the prevalence of asthma in people aged 20 and above is about 4.2%, with approximately 47.5 million people nationwide. Including those under 20, there are approximately 60 million asthma patients in China; Chronic obstructive pulmonary disease also affects more than 300 million people worldwide, causing 3 million deaths annually, making it the fifth leading cause of death globally and one of the five most expensive common diseases to treat.
TSLP, as an epithelial cell cytokine, plays a key role in the occurrence and persistence of airway inflammation. It is reported that TSLP inhibition is currently the only confirmed biological method with clinical benefits for various patients with moderate-to-severe asthma. Tezepelumab, a TSLP monoclonal antibody developed by AstraZeneca and Amgen, was approved by the FDA at the end of 2021. Public information shows that in the first three quarters of 2023, tezepelumab sales reached US$230 million, exceeding the US$174 million in sales for the whole of 2022. The industry is very optimistic about the market application prospects of drug research using TSLP as an important target, with broad development space in this field.
About Joincare

Joincare Pharmaceutical Group was founded in 1992. After years of steady operation and rapid development, it has become an innovative and research-oriented comprehensive pharmaceutical group. It owns two large listed companies, Joincare (600380.SH) and Lizhu Pharmaceutical (000513.SZ, 1513.HK), and more than 20 major subsidiaries. Joincare has always adhered to technological innovation as its strategic foundation and aims to drive innovation with both innovative drugs and high-barrier complex preparation technology platforms. It has established a rich pipeline around areas with significant clinical needs, such as respiratory, analgesia, digestive tract, assisted reproduction, mental health, and oncology, forming a rich and diverse product matrix and R&D drug pipeline. Data shows that Joincare ranked 6th in terms of revenue among comprehensive pharmaceutical companies in China in 2021 and 5th in R&D investment, which is at a high level in the same industry.
About Quansin Bio

Quansin Bio was established in 2015. It is a clinical-stage innovative enterprise focusing on biotherapies for autoimmune and allergic diseases. It has a completely self-developed drug pipeline and mature commercial-scale internal production capacity. Quansin Bio adheres to the development concept of "innovation for the greatest number of patients" and strives to solve the problems of drug accessibility and affordability in the areas of concern.
Based on its complete independent innovation capabilities, the company has now formed a product pipeline containing multiple innovative products, including one product with an accepted BLA, one product in Phase III clinical trials, and four products in Phase II and I clinical trials respectively. The indications cover four major disease areas: skin, rheumatism, respiratory, and digestive, including psoriasis, atopic dermatitis, ankylosing spondylitis, systemic lupus erythematosus, asthma, and inflammatory bowel disease. It is one of the companies in China with the most IND approvals in the field of autoimmune and allergic diseases.